---
title: Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
date: '2024-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39556016/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241118172045&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: A single infusion of RP-A501 appeared to be safe and was
  associated with cardiac LAMP2 expression and evidence of clinical improvement over
  a period of 24 to 54 months. (Funded by Rocket Pharmaceuticals; ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: A single infusion of RP-A501 appeared to be safe and was associated with cardiac LAMP2 expression and evidence of clinical improvement over a period of 24 to 54 months. (Funded by Rocket Pharmaceuticals; ClinicalTrials.gov number, ...